For example, several meta-analyses have demonstrated a reduced incidence of obesity-related cancers, including colorectal and prostate cancers, among patients using GLP-1RAs compared to those on insulin therapy. This evidence concerns the gene INS and obesity due to melanocortin 4 receptor deficiency.